Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir

Author:

Zimba Stanley1ORCID,Mbewe Nyuma2,Chishimba Lorraine3,Chomba Mashina3,Saylor Deanna45

Affiliation:

1. Internal Medicine Consultant and Neurology Registrar, Department of Internal Medicine, University Teaching Hospital, Lusaka, Zambia

2. Infectious Diseases Registrar, Department of Internal Medicine, University Teaching Hospital, Lusaka, Zambia

3. Neurology Registrar, Department of Internal Medicine, University Teaching Hospital, Lusaka, Zambia

4. Honorary Consultant, University Teaching Hospital, Lusaka, Zambia

5. Assistant Professor of Neurology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

In 2016, the World Health Organization adopted dolutegravir (DTG)-based antiretroviral therapy as an alternative first-line treatment of HIV after many clinical trials showed that it was more effective, better tolerated and more protective than efavirenz and boosted protease inhibitors against discontinuation of treatment from adverse drug reactions. However, there was concern that DTG would lead to increased rates of immune reconstitution inflammatory syndrome (IRIS), especially in the setting of late presentation to care. Three cases at the University Teaching Hospital in Lusaka, Zambia highlight this concern, especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) co-infection.

Publisher

SAGE Publications

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Dolutegravir/lamivudine/tenofovir;Reactions Weekly;2021-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3